ConCallIQ
Go Pro
DRREDDY Diversified 08 May 2024

Dr. Reddy's Laboratories Limited — Q4 FY24

Dr.

bullish high
Compare with...
Revenue ₹7,083 Cr +12%
EBITDA ₹1,872 Cr +15%
PAT ₹1,307 Cr +36%
EBITDA Margin 26.4% +53bps
Duration
Read Time 1 min read

✓ Verified against BSE filing

Delivery score0%
Due this quarter1
Delivered0
Missed1

Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.

Q3 FY24

SG&A investments to continue at elevated levels

SG&A spend will remain higher in absolute terms as investments in brands and pipeline products continue, with revenue growth expected to provide operating leverage.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1